SOAT1 and primary cutaneous T-cell non-Hodgkin lymphoma: Janus kinase (JAK) inhibitors offer a targeted therapeutic approach, aiming to suppress this dysregulation by preventing the phosphorylation and activation of JAK and STAT proteins, thereby impeding the progression of CTCL [23,24].